These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34504395)

  • 1. The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis.
    Hu S; Lin C; Cai X; Zhu X; Lv F; Nie L; Ji L
    Mediators Inflamm; 2021; 2021():7712587. PubMed ID: 34504395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis.
    Karpouzas GA; Ormseth SR; van Riel PLCM; Gonzalez-Gay MA; Corrales A; Rantapää-Dahlqvist S; Sfikakis PP; Dessein P; Tsang L; Hitchon C; El-Gabalawy H; Pascual-Ramos V; Contreras-Yáñez I; Colunga-Pedraza IJ; Galarza-Delgado DA; Azpiri-Lopez JR; Semb AG; Misra DP; Hauge EM; Kitas G
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39043615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.
    Sparks JA; Lesperance T; Accortt NA; Solomon DH
    Arthritis Care Res (Hoboken); 2019 Apr; 71(4):512-520. PubMed ID: 29799667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis.
    Barnabe C; Martin BJ; Ghali WA
    Arthritis Care Res (Hoboken); 2011 Apr; 63(4):522-9. PubMed ID: 20957658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs.
    Solomon DH; Curtis JR; Saag KG; Lii J; Chen L; Harrold LR; Herrinton LJ; Graham DJ; Kowal MK; Kuriya B; Liu L; Griffin MR; Lewis JD; Rassen JA
    Am J Med; 2013 Aug; 126(8):730.e9-730.e17. PubMed ID: 23885678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX; Liang S; Gao L; Liu H
    PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
    Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.
    Greenberg JD; Kremer JM; Curtis JR; Hochberg MC; Reed G; Tsao P; Farkouh ME; Nasir A; Setoguchi S; Solomon DH;
    Ann Rheum Dis; 2011 Apr; 70(4):576-82. PubMed ID: 21109516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.
    Meissner Y; Zink A; Kekow J; Rockwitz K; Liebhaber A; Zinke S; Gerhold K; Richter A; Listing J; Strangfeld A
    Arthritis Res Ther; 2016 Aug; 18(1):183. PubMed ID: 27495156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential benefits of biologics on stroke and mortality in patients with rheumatoid arthritis: A nationwide population-based cohort study in Taiwan.
    Tang CH; Yu F; Huang CY; Chen DY
    Int J Rheum Dis; 2019 Aug; 22(8):1544-1552. PubMed ID: 31240863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis.
    Jorge A; Lu N; Choi H; Esdaile JM; Lacaille D; Avina-Zubieta JA
    Arthritis Care Res (Hoboken); 2023 Apr; 75(4):743-748. PubMed ID: 34941008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H; Frisell T; Askling J;
    JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis.
    Castagné B; Viprey M; Martin J; Schott AM; Cucherat M; Soubrier M
    PLoS One; 2019; 14(8):e0220178. PubMed ID: 31369575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.
    Buch MH; Bhatt DL; Charles-Schoeman C; Giles JT; Mikuls T; Koch GG; Ytterberg S; Nagy E; Jo H; Kwok K; Connell CA; Masri KR; Yndestad A
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38609322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.
    Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Siu S; Kraft J; Lynde C; Pope J; Gulliver W; Keeling S; Dutz J; Bessette L; Bissonnette R; Haraoui B
    Ann Rheum Dis; 2015 Mar; 74(3):480-9. PubMed ID: 25561362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Singh S; Fumery M; Singh AG; Singh N; Prokop LJ; Dulai PS; Sandborn WJ; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Apr; 72(4):561-576. PubMed ID: 30875456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
    Naranjo A; Sokka T; Descalzo MA; Calvo-Alén J; Hørslev-Petersen K; Luukkainen RK; Combe B; Burmester GR; Devlin J; Ferraccioli G; Morelli A; Hoekstra M; Majdan M; Sadkiewicz S; Belmonte M; Holmqvist AC; Choy E; Tunc R; Dimic A; Bergman M; Toloza S; Pincus T;
    Arthritis Res Ther; 2008; 10(2):R30. PubMed ID: 18325087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
    Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
    Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs.
    Xie F; Chen L; Yun H; Levitan EB; Curtis JR
    J Rheumatol; 2021 Jun; 48(6):804-812. PubMed ID: 33060309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.